Aurora Cannabis Return on Equity

Aurora Cannabis (ACB.TO) currently reports a ROE of -21.3%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Aurora Cannabis's ROE history and peer comparisons.

Aurora Cannabis's ROE of -21.3% is higher than the Healthcare sector average of -75.84%. That is roughly 71.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Aurora Cannabis's current -21.3% should be judged against Healthcare norms (sector average: -75.84%) and against ACB.TO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -21.3%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Aurora Cannabis, and consider following ACB.TO for alerts when major investors trade the stock.

Aurora Cannabis is classified in the Healthcare sector. On ROE, it currently shows -21.3% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACB.TO with unrelated industries.